Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone

Purpose/Objective(s) Skeletal-related events (SREs), which include radiation to the bone (RtB), can occur among patients with bone metastasis (BM). There is a recognized potential for misclassification of RtB when using claims data. We compared alternative measures of RtB to better understand their impact on SRE prevalence and SRE-related mortality. Methods and materials We analyzed data for stage IV prostate cancer (PCa) cases identified between 2005 and 2009 in the Surveillance, Epidemiology, and End Results registry linked with Medicare claims. We created two measures of RtB: 1) a literature-based measure requiring the presence of a prior claim with a BM code; 2) a new measure requiring either that the BM code coincided with the radiation episode or that the duration of the radiation episode was less than or equal to 4 weeks. We estimated adjusted hazard ratios of an SRE using both measures among stratified samples: no metastasis (M0), metastasis to bone (M1b) and other sites (M1c). Results The study sample included 5,074 men with stage IV PCa (median age 77 years), of whom 22% had M0, 54% had M1b, and 24% had M1c disease at time of PCa diagnosis. Based on Approaches 1 and 2, the proportion with probable RtB was 5% and 8% among M0, 30% and 30% among M1b, and 25% and 27% among M1c patients. Among M0 patients, the adjusted hazard ratio (AHR) associated with an SRE was 1.27 when using Approach 1 (95% confidence interval, CI: 0.95–1.7) and 1.49 when using Approach 2 (95% CI: 1.14–1.96). However, the impact of SREs on mortality did not differ between both approaches among M1b and M1c patients. Conclusion We found that alternative measures used to define RtB as SRE in claims data impact conclusions regarding the effect of SREs on mortality among M0 but not M1 patients.

[1]  Nikki M. Carroll,et al.  Validating Billing/Encounter Codes as Indicators of Lung, Colorectal, Breast, and Prostate Cancer Recurrence Using 2 Large Contemporary Cohorts , 2014, Medical care.

[2]  Ronald C. Chen,et al.  Considerations for observational research using large data sets in radiation oncology. , 2014, International journal of radiation oncology, biology, physics.

[3]  C. Mullins,et al.  Skeletal-related events and mortality among older men with advanced prostate cancer. , 2014, Journal of geriatric oncology.

[4]  J. Debus,et al.  Palliative radiation therapy in patients with metastasized pancreatic cancer - description of a rare patient group , 2014, European Journal of Medical Research.

[5]  C. Mullins,et al.  Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer , 2014, Current opinion in oncology.

[6]  Eberechukwu Onukwugha,et al.  Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer , 2014, BMC Medical Research Methodology.

[7]  C. Mullins,et al.  The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer , 2014, PharmacoEconomics.

[8]  Ben Shneiderman,et al.  Temporal Event Sequence Simplification , 2013, IEEE Transactions on Visualization and Computer Graphics.

[9]  Eberechukwu Onukwugha,et al.  Variation in the Length of Radiation Therapy Among Men Diagnosed With Incident Metastatic Prostate Cancer , 2013 .

[10]  F. Saad,et al.  Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. , 2012, European journal of cancer.

[11]  M L Kilgore,et al.  Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006 , 2011, Prostate Cancer and Prostatic Diseases.

[12]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[13]  Xue Song,et al.  Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. , 2010, Journal of managed care pharmacy : JMCP.

[14]  Henrik Toft Sørensen,et al.  Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). , 2010, The Journal of urology.

[15]  A. D'Amico,et al.  NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  David J Harrison,et al.  The cost of treating skeletal-related events in patients with prostate cancer. , 2008, The American journal of managed care.

[17]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  R. Coleman Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[19]  K. Weinfurt,et al.  The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  F. Saad,et al.  Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. , 2004, European urology.

[21]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[22]  J. Coresh,et al.  Adjusting survival curves for confounders: a review and a new method. , 1996, American journal of epidemiology.